en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2023
vol. 98
 
Share:
Share:
abstract:
Original paper

A recent overview of non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: pathophysiology, recognition, and management

Rafał Podgórski
1
,
Dominika Podgórska
2
,
Marta Sumińska
3

1.
Department of Biochemistry, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
2.
Department of Internal Medicine, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
3.
Department of Paediatric Diabetes, Auxology and Obesity, Institute of Paediatrics, Poznan University of Medical Sciences, Poznan, Poland
Pediatr Pol 2023; 98 (4): 307-319
Online publish date: 2023/12/15
View full text Get citation
 
PlumX metrics:
Congenital adrenal hyperplasia (CAH) is defined as a group of congenital, autosomal, and recessive disorders associated with functional limitations or deficiency of one of the key enzymes in the biosynthesis of steroid hormones leading to hypocortisolaemia and most frequently excessive androgen production. The most common abnormality is associated with 21-hydroxylase deficiency. Activity at the level of 20–70% of normal enzyme function leads to the development of a non-classic form of congenital adrenal hyperplasia (NCAH). In contrast to classic CAH, patients with NCAH manifest normal or partially mild cortisol deficiency and moderate hyperandrogenism without a deficit of mineralocorticoids. Due to nonspecific symptoms, NCAH is often never recognized or is misdiagnosed with polycystic ovary syndrome (PCOS). Recognition can be based on the measurement of 17-hydroxyprogesterone (17OHP) for screening purposes, but the cosyntropin stimulation test with a measurement of 17OHP should be the gold standard. Pharmacological treatment is initiated only in those who manifest significant clinical symptoms.
keywords:

non-classic congenital adrenal hyperplasia, NCAH, androgen excess, NCAH diagnosis